[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645163":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":45,"collaborators":20,"id":47,"slug":20,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":20,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DLL3-targeted PET\u002FCT","EXPERIMENTAL","Each subject receives a single intravenous injection of DLL3-targeted probe and undergoes PET\u002FCT imaging within the specified time.",[13],"Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET\u002FCT), DLL3-targeted PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","conventional imaging (CT, MRI or 18F-FDG PET\u002FCT), DLL3-targeted PET\u002FCT","Participants will undergo DLL3-Targeted PET\u002FCT imaging for the evaluation of tumor lesions. Imaging findings will be compared with conventional imaging modalities as part of the study analysis.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Liang Zhao","CONTACT","86 18818350620","wzhaoliang01@163.com",{"name":28,"role":24,"phone":20,"phoneExt":20,"email":29},"Haojun Chen","leochen0821@foxmail.com",[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Xiamen","Fujian","361000","China",{"type":38,"coordinates":39},"Point",[40,41],118.08187,24.47979,{"lat":41,"lon":40},[44],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":46,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100645163",false,"NCT07677787","DLL3-Targeted PET\u002FCT in Small Cell Lung Cancer","Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Small Cell Lung Cancer","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with suspected, newly diagnosed, and previously treated small cell lung cancer(supporting evidence may include imaging findings and pathology report);\n* Serum ProGRP or NSE level ≥ 3 times the upper limit of normal;\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n* Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.\n* Inability to complete PET\u002FCT imaging.","ALL","18 Years","80 Years",{"count":57,"type":58},20,"ESTIMATED","INTERVENTIONAL",[61],"NA","The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET\u002FCT in patients with suspected or histologically confirmed small cell lung cancer, and to compare with conventional imaging modalities.",[64,65,9,66],"PET\u002FCT","Small Cell Lung Cancer ( SCLC )","Delta-like Protein 3",[9,64,68,69,70],"Small Cell Lung Cancer","SCLC","Delta-like protein 3","2026-06-25",{"date":73,"type":74},"2026-07-01","ACTUAL",{"date":76,"type":74},"2026-05-09",{"date":78,"type":58},"2028-05-31",{"name":5,"class":6},1]